Altre lingue Aligos Therapeutics, Inc.

Azioni

ALGS

US01626L1052

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:00 03/05/2024			Variaz. 5gg	Var. 1 gen.
0,8101 ^USD	-4,24%		+3,59%	+22,00%

03/04	Aligos Therapeutics, Inc. annuncia il dosaggio dei primi soggetti nello studio HERALD di Fase 2a di ALG-055009 in soggetti MASH	CI
27/03	Aligos Therapeutics presenta all'APASL 2024 dati clinici positivi dagli studi di fase 1 ALG-055009 e ALG-000184	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024	30/04
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024	30/04
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study	25/04
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study	25/04
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD	25/04
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD	25/04
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024	09/04
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	03/04
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	03/04
Aligos Therapeutics, Inc. Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	03/04
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies	27/03
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies	27/03
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	18/03
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects	18/03
Aligos Therapeutics, Inc. Announces the Initiation of the Phase 2a HERald Study of ALG-055009 in MASH Subjects	18/03
Aligos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results	12/03
Aligos Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12/03
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024	05/03
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024	26/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Aligos Therapeutics, Inc.

Azioni

ALGS

US01626L1052

Altre lingue

Filtri